Martine Zimmermann
Director/Board Member chez INVENTIVA
Fortune : 167 034 $ au 31/03/2024
Postes actifs de Martine Zimmermann
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INVENTIVA | Director/Board Member | 16/04/2021 | - |
| Independent Dir/Board Member | 16/04/2021 | - | |
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26/09/2023 | - |
| Independent Dir/Board Member | 26/09/2023 | - | |
| Ipsen Biopharmaceuticals, Inc. | General Counsel | - | - |
Historique de carrière de Martine Zimmermann
Anciens postes connus de Martine Zimmermann
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/06/2016 | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01/03/2019 | 01/01/2021 |
Formation de Martine Zimmermann
| University of Strasbourg | Doctorate Degree |
| Louis Pasteur University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| France | 4 |
Opérationnelle
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| General Counsel | 2 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| INVENTIVA | Health Technology |
| Entreprise privées | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Martine Zimmermann
- Expérience
